---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002102"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:24:50.657875+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Novavax appoints John C. Jacobs as CEO; Stanley Erck retires effective Jan 23, 2023

## Summary
- John C. Jacobs appointed President and CEO, effective January 23, 2023, succeeding retiring CEO Stanley C. Erck.
- Jacobs receives $700k base salary, 75% target bonus, and inducement grants (options + RSUs) worth ~$6M combined.
- Erck to provide advisory services through April 2024 at $50k/month for 6 months, then $25k/month, with equity treatment.
- Board adopted 2023 Inducement Plan reserving 1 million shares for new-hire equity grants under Nasdaq Rule 5635(c)(4).

## SEC filing metadata
- accession: 0001104659-23-002102
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/0001104659-23-002102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/tm232657d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002102
- JSON: https://secwatch.observer/filing/0001104659-23-002102.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002102.txt

## Key facts
- Executive change
  Stanley C. Erck retired as President and Chief Executive Officer at NOVAVAX INC.
  - Action: retired
  - Role: President and Chief Executive Officer
  source text: Mr. Jacobs will succeed Stanley C. Erck, who provided the Board with notice on January 5, 2023 of his decision to retire as President and Chief Executive Officer and as a member of the Board, in each case effective as of January 23, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/0001104659-23-002102-index.htm
- Executive change
  John C. Jacobs was appointed as President and Chief Executive Officer at NOVAVAX INC.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”) approved the appointment of John C. Jacobs, age 56, as President and Chief Executive Officer and a member of the Board, effective as of January 23, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/0001104659-23-002102-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.